Franziska Cygon

Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma

Hans‐Joachim Schmoll, Lars H. Lindner, Peter Reichardt et al. · JAMA Oncology · 2020 · 31 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.

Hans‐Joachim Schmoll, Fabian Maximilian Meinert, Franziska Cygon et al. · Journal of Clinical Oncology · 2017 · 19 citations

Pharmacy, Oncology, Pharmacotherapy +13

FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

Hans‐Joachim Schmoll, Benjamin Garlipp, Christian Junghanß et al. · Annals of Oncology · 2018 · 15 citations · Full text

Medicine, Oncology, Pharmacology +13

Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

Hans‐Joachim Schmoll, Julia Mann, Fabian Maximilian Meinert et al. · British Journal of Cancer · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +13